inhibitor of DNA binding 4Genealiases: IDB4 · bHLHb27
Q-omics provides the consensus-scored ID4 profile across patient tissues and cancer cell-line models. ID4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ID4 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, ID4 RNA expression shows 17,408 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where ID4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ID4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ID4 survival associations across molecular data types. ID4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ID4 RNA expression–survival associations across cancer types. High ID4 expression shows unfavorable associations in COAD, but favorable associations in KIRC, UCEC, BLCA, LAML and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ID4 RNA expression.
This table summarizes ID4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ID4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ID4 shows lower tumor expression in KICH, THCA, HNSC, LUAD, LUSC and STAD. The KICH box plot shows higher ID4 RNA expression in normal versus tumor tissue (log2 FC = −4.453, t-test p < 0.001).
This table shows molecular features associated with ID4 in patient tissues and cancer cell lines. In patient samples, ID4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ID4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
